Exagen Inc (XGN) Stock Analysis

Exagen Inc (XGN) is a publicly traded company in the HEALTHCARE sector. It trades at $4.82, carries a market capitalization of $129.25M. This page summarizes the public market data, fundamentals, and frequently asked questions for XGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

• Price: $4.82
• Market Cap: $129.25M
• EPS: $-0.90
• 52-Week High: $12.23
• 52-Week Low: $2.59

Market Sentiment

Exagen Inc currently has a Bullish sentiment score of 0.35.

About Exagen Inc

Exagen Inc. is a pioneering biotechnology company based in Vista, California, specializing in diagnostic solutions for autoimmune diseases utilizing its proprietary Cell-Bound Complement Activation Products technology, known as AVISE. Committed to improving patient care, Exagen offers innovative diagnostic tests that facilitate precise diagnosis and management of complex conditions like lupus and various inflammatory diseases. Through a strong focus on clinical validation and innovation, the ...

GNG Research Analysis

GNG Research scores Exagen Inc (XGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XGN.

Frequently Asked Questions

Does XGN pay dividends?

Exagen Inc (XGN) does not currently pay a regular dividend.

What is XGN's market cap?

Exagen Inc (XGN) has a market capitalization of $129.25M with a current stock price of $4.82.